2.1 ACE Inhibitors versus ARBs

Despite similar mechanisms targeting the RAAS, ACE inhibitors and ARBs demonstrate important differences in clinical outcomes for heart failure patients.

A meta-analysis by van Vark et al. demonstrated that ACE inhibitors reduce all-cause mortality with a hazard ratio of 0.90 (p=0.004) compared to placebo, while ARBs showed no significant mortality benefit (HR 0.99, p=0.68).[4] This translates to dramatically different numbers needed to treat: approximately 70 patients with ACE inhibitors versus 446 with ARBs to prevent one death.[5]

The differential benefit appears attributable to the additional mechanisms of ACE inhibitors beyond simple angiotensin II blockade. ACE inhibitors decrease bradykinin degradation, leading to increased release of nitric oxide and prostaglandins with resulting additional vasodilation and cardioprotective effects.[5] This bradykinin-potentiating effect may explain the superior coronary protection seen with ACE inhibitors (NNT=54) compared to ARBs (NNT=3,580).[5]

In direct head-to-head analyses, ACE inhibitors and ARBs show similar efficacy for major clinical outcomes.[6] However, when each is compared to placebo, important differences emerge, with ACE inhibitors consistently demonstrating mortality benefits not seen with ARBs. When specifically examining heart failure with reduced ejection fraction (HFrEF), ACE inhibitors reduce all-cause mortality by approximately 11% and cardiovascular mortality by about 14%, while ARBs generally fail to show significant mortality reduction.[6]

2.2 Angiotensin Receptor-Neprilysin Inhibitors (ARNIs)

ARNIs represent a significant advancement in RAAS modulation for heart failure. The combination of sacubitril (a neprilysin inhibitor) and valsartan (an ARB) enhances levels of beneficial natriuretic peptides while simultaneously blocking angiotensin II effects.

The landmark PARADIGM-HF trial established the superiority of sacubitril/valsartan over enalapril in patients with HFrEF. However, these medications require monitoring for [[hyperkalemia-treatment-report|hyperkalemia]] and potential [[aki_workup_summary|kidney injury]]. The study demonstrated a 20% reduction in the primary composite endpoint of cardiovascular death or heart failure hospitalization (HR 0.80, 95% CI 0.73-0.87, p<0.001) and a 16% reduction in all-cause mortality (HR 0.84, 95% CI 0.76-0.93, p<0.001).[7]

This translates to an absolute risk reduction of approximately 4.7% for the combined endpoint, indicating that 21 patients need to be treated with sacubitril/valsartan instead of enalapril to prevent one heart failure hospitalization or cardiovascular death over 27 months.[7] For all-cause mortality, the absolute risk reduction was 2.8% (NNT=36), and for cardiovascular mortality specifically, the absolute risk reduction was 3.2% (NNT=31).

The benefits of ARNI therapy emerge rapidly after initiation, with analyses showing significant reductions in heart failure hospitalization within 30 days of treatment initiation.[8] This early benefit supports the concept of initiating ARNI therapy promptly rather than waiting for clinical deterioration on ACE inhibitors or ARBs.

Table 1a. Comparative Efficacy of ARNI vs ACE-I in HFrEF (PARADIGM-HF Trial)

2.3 Impact in Clinical Practice

The aggregate treatment effect of comprehensive GDMT including ARNI is substantial. Analysis from the Get With The Guidelines-Heart Failure (GWTG-HF) registry demonstrated that using all four pillars of modern heart failure therapy reduces all-cause mortality by approximately 24.8% compared to no GDMT.[9] This translates to only four patients needing treatment with quadruple therapy to prevent one death.

Current guidelines now recommend ARNI as the preferred RAAS inhibitor for patients with HFrEF who can tolerate it.[10] However, despite clear evidence of benefit, implementation in real-world practice remains suboptimal, with only 15.3% of eligible patients receiving quadruple therapy including ARNI.[9]

3.1 Steroidal MRAs: Established Benefits and Limitations

Steroidal MRAs (spironolactone and eplerenone) have well-established benefits in heart failure based on landmark trials. In the RALES trial, spironolactone reduced all-cause mortality by 30% in patients with severe HFrEF (NYHA class III-IV) with an NNT of only 10, representing an absolute risk reduction of 11.0% (mortality rates 46% vs. 35%).[11] The EMPHASIS-HF trial subsequently demonstrated that eplerenone reduced cardiovascular death or heart failure hospitalization by 37% in patients with mild HFrEF (NYHA class II) with an NNT of 13, representing an absolute risk reduction of 7.6% (event rates 29.1% vs. 21.5%).[12]

Table 2a. Major MRA Trials: Absolute Risk Reduction and NNT

Despite their proven benefits, steroidal MRAs have important limitations: 1. High rates of hyperkalemia, particularly in patients with reduced kidney function (absolute increase of 5-10% over placebo) 2. Significant endocrine side effects, especially with spironolactone (gynecomastia in 10% of men with an absolute difference of 9% compared to placebo) 3. Predominantly kidney-focused tissue distribution that may limit cardiac effects 4. Underutilization in clinical practice due to safety concerns

3.2 Non-Steroidal MRAs: Emerging Evidence

Non-steroidal MRAs like finerenone offer several potential advantages: 1. Balanced heart-kidney tissue distribution 2. Superior selectivity for the mineralocorticoid receptor 3. Minimal off-target effects on androgen and progesterone receptors 4. Reduced risk of hyperkalemia compared to steroidal agents

The ARTS-HF trial directly compared finerenone with eplerenone in patients with heart failure and reduced ejection fraction who also had diabetes and chronic kidney disease. Finerenone demonstrated similar efficacy in reducing NT-proBNP levels but with significantly lower rates of hyperkalemia and less decline in kidney function.[13]

More recently, the FINEARTS-HF trial evaluated finerenone in patients with heart failure with preserved ejection fraction (HFpEF), demonstrating a significant 29% reduction in the composite of total heart failure events and cardiovascular death compared to placebo (HR 0.71, 95% CI 0.60-0.85, p<0.001).[14] This represents one of the few positive trials in the challenging HFpEF population.

3.3 Differential Effects by Heart Failure Phenotype

A landmark individual patient-level meta-analysis published in The Lancet in 2024 revealed important differences in treatment effects by heart failure phenotype.[14] This analysis found that:

1. Steroidal MRAs (spironolactone and eplerenone) demonstrated significant reduction in cardiovascular death or heart failure hospitalization in patients with HFrEF

2. Non-steroidal MRAs (finerenone) showed significant reduction in cardiovascular death or heart failure hospitalization in HFmrEF/HFpEF

This pattern suggests that the optimal MRA class may differ based on ejection fraction phenotype - a paradigm-shifting concept that challenges the traditional approach of treating all MRAs as essentially interchangeable agents with different side effect profiles.

3.4 Considerations in Patients with Kidney Disease

For patients with both heart failure and chronic kidney disease, the evidence increasingly favors non-steroidal MRAs, particularly as kidney function declines:

1. In patients with eGFR >45-60 ml/min/1.73m², steroidal MRAs maintain robust mortality evidence but require careful monitoring

2. In patients with eGFR 30-45 ml/min/1.73m², evidence increasingly favors non-steroidal MRAs due to lower hyperkalemia risk and potential direct renoprotective effects

3. In patients with eGFR <30 ml/min/1.73m², evidence for either class is limited, but non-steroidal MRAs appear to offer a better safety profile

The non-steroidal MRA finerenone has established itself as a foundational guideline-recommended therapy in diabetic kidney disease, with strong evidence from dedicated trials.[15] This makes it particularly attractive for the common scenario of combined heart failure and diabetic kidney disease.

4.1 Natriuretic Peptide Physiology and Resistance Development

Natriuretic peptides serve as counter-regulatory hormones that promote natriuresis, vasodilation, and inhibit the RAAS and sympathetic nervous systems. However, their effectiveness diminishes as heart failure progresses - a phenomenon known as natriuretic peptide resistance.

Natriuretic peptide resistance develops through several mechanisms: 1. Receptor downregulation after chronic exposure to high levels 2. Post-receptor signaling defects 3. Enhanced degradation by neprilysin and other proteases 4. Production of biologically inactive fragments

The development of resistance follows a continuum rather than a sudden shift, but evidence suggests certain clinical thresholds where resistance becomes more pronounced. This is particularly relevant in patients progressing to [[Stages-Progression|advanced CKD]] or requiring [[dialysis_student_guide|renal replacement therapy]].:

1. Early resistance begins to develop in NYHA class II heart failure or CKD stage 3a, but often remains subclinical
2. Clinically significant resistance typically manifests in NYHA class III or CKD stage 3b-4
3. Advanced resistance with minimal remaining natriuretic peptide effect is generally seen in NYHA class IV or CKD stage 5[17,18]

4.2 Biomarker Thresholds Indicating Resistance

Several biomarker thresholds have been associated with natriuretic peptide resistance:

1. NT-proBNP levels >1,000 pg/ml correlate with the onset of measurable natriuretic peptide receptor downregulation, but more significant resistance typically develops once levels exceed 3,000-4,000 pg/ml[7]

2. The ratio of cGMP (the second messenger for natriuretic peptide signaling) to BNP provides insights into pathway responsiveness. Studies show that cGMP/BNP ratios <0.15 pmol/pg are strongly associated with established natriuretic peptide resistance[18]

3. Spot urine sodium concentration <50-70 mmol/L after loop diuretic administration strongly correlates with diuretic and natriuretic peptide resistance[19]

4.3 Implications for ARNI Therapy

The concept of natriuretic peptide resistance has important implications for ARNI therapy:

1. Theoretically, neprilysin inhibition may offer greatest benefit when initiated before significant natriuretic peptide resistance develops

2. However, clinical trial evidence shows more nuanced outcomes. In PARADIGM-HF, the relative risk reduction with sacubitril/valsartan was consistent across NYHA classes and NT-proBNP quartiles, though there was a trend toward attenuated benefit in the highest NT-proBNP quartile (>2,995 pg/ml)[7]

3. PIONEER-HF demonstrated that the relative NT-proBNP reduction with sacubitril/valsartan was greater in patients with de novo heart failure compared to those with acute-on-chronic decompensation (61% vs. 46% reduction), suggesting better responsiveness in newer-onset disease[20]

This evidence supports the concept of earlier ARNI initiation while acknowledging that clinically meaningful benefits extend across the spectrum of heart failure severity, even in populations with expected natriuretic peptide resistance.

4.4 BNP as a Hormone More Effective in Health Than Disease

An important conceptual framework for understanding heart failure progression is that BNP functions as a homeostatic hormone that loses effectiveness in advanced disease, while other neurohormones like aldosterone and vasopressin (ADH) maintain or increase their biological importance.

In healthy individuals, BNP serves primarily as a counter-regulatory hormone that balances the effects of RAAS and sympathetic activation. As heart failure progresses, several changes occur:

1. BNP effectiveness diminishes due to receptor downregulation and signaling defects
2. Aldosterone and vasopressin pathways maintain their effectiveness or even upregulate
3. The relative importance shifts from natriuretic peptides toward aldosterone and vasopressin

This shifting balance helps explain why therapies targeting the RAAS and aldosterone (ACE inhibitors, ARBs, and MRAs) maintain their effectiveness even in advanced heart failure, while strategies solely enhancing natriuretic peptides may show diminishing returns in more advanced disease.[21]

5.1 Serial Natriuretic Peptide Monitoring

Several landmark trials have evaluated whether using serial BNP or NT-proBNP measurements to guide therapy improves outcomes compared to standard clinically-guided care:

The TIME-CHF trial randomized 499 patients with heart failure to NT-proBNP-guided treatment versus symptom-guided treatment. The primary outcome of survival free from hospitalization was not significantly improved in the overall population, but patients younger than 75 years showed benefit with biomarker-guided therapy.[22]

The GUIDE-IT trial was designed to be the definitive study of natriuretic peptide-guided therapy, planning to enroll 1,100 patients with HFrEF. The trial was stopped early for futility after 894 patients, as NT-proBNP-guided therapy did not improve the composite of time to first HF hospitalization or cardiovascular mortality compared with usual care.[23]

A comprehensive individual patient-data meta-analysis of 2,431 patients from eight randomized trials showed that NT-proBNP-guided therapy was associated with an 18% reduction in all-cause mortality compared with clinically guided therapy. The benefit was most pronounced in patients <75 years old and those with HFrEF rather than HFpEF.[24]

The 2022 AHA/ACC/HFSA Heart Failure Guidelines give a Class 2a recommendation (Level of Evidence B-R) for measuring natriuretic peptide biomarkers during hospitalization for heart failure and after discharge. However, they give a Class 2b recommendation (Level of Evidence B-R) for using biomarker-guided therapy, noting inconsistent evidence across trials.[10]

5.2 Special Considerations with ARNI Therapy

When interpreting natriuretic peptide levels in patients receiving sacubitril/valsartan, it’s important to note that BNP is a substrate for neprilysin and levels increase with neprilysin inhibition independent of heart failure status. Therefore, NT-proBNP (which is not a substrate for neprilysin) is the preferred biomarker for monitoring patients on ARNI therapy.[25]

5.3 Spot Urine Sodium for Assessing Resistance

Spot urine sodium concentration provides valuable insights into diuretic and natriuretic peptide responsiveness. In normal physiology, natriuretic peptides promote sodium excretion, resulting in higher urinary sodium concentrations. As natriuretic peptide resistance develops, this response becomes blunted.

Studies examining the relationship between spot urine sodium and diuretic resistance have found that urinary sodium concentration <50-70 mmol/L after loop diuretic administration strongly correlates with diuretic resistance and poor clinical outcomes in heart failure.[19]

In contemporary practice, spot urine sodium measurement can identify patients with diuretic and/or BNP resistance using the following thresholds: - >70-100 mmol/L: Normal natriuretic response - 50-70 mmol/L: Mild resistance - 20-50 mmol/L: Moderate resistance - <20 mmol/L: Severe resistance[17]

5.4 Inpatient Monitoring

While NT-proBNP provides valuable prognostic information at admission and discharge, daily measurements during hospitalization have not been shown to definitively improve outcomes or decision-making compared to careful clinical assessment and more established monitoring parameters.

Several important limitations affect the interpretation of daily NT-proBNP measurements: 1. Significant lag time exists between clinical improvement and biomarker changes 2. Day-to-day variations of 15-20% can occur due to analytical variability 3. The half-life of NT-proBNP means that significant changes typically require 1-2 days

A pragmatic approach includes obtaining NT-proBNP at admission and discharge, with perhaps one additional measurement at the midpoint of hospitalization if clinical response is unclear.[26]

6.1 Timing of Intervention

The concept of “the earlier the better” for initiation of GDMT is supported by multiple lines of evidence:

1. Benefits of comprehensive GDMT emerge rapidly, with reductions in heart failure hospitalization observed within 30 days of treatment initiation[8]

2. Delaying optimal therapy results in preventable events during the waiting period, as demonstrated in PARADIGM-HF analyses showing early divergence of event curves[7]

3. Pathophysiologically, earlier intervention may preserve cardiac function before irreversible remodeling and fibrosis develop

4. The window of opportunity for maximal natriuretic peptide system enhancement may close as resistance develops with disease progression

Current guidelines now recommend rapid initiation and titration of the “4 pillars” of GDMT to maximize early benefits. The target is reaching maximally tolerated doses of all four medication classes within 3 months of diagnosis.[3]

6.2 Sequencing and Phenotype-Guided Approaches

The optimal approach to heart failure management increasingly appears to involve phenotype-guided medication selection:

1. HFrEF:
   • ARNI preferred over ACE-I/ARB when tolerated
   • Steroidal MRAs (spironolactone, eplerenone) appear more beneficial based on the 2024 Lancet meta-analysis[14]
   • Rapid initiation of all four pillars recommended
2. HFpEF:
   • SGLT2 inhibitors have the strongest evidence base
   • ARNI and non-steroidal MRAs show promise where traditional therapies have failed
   • Phenotype-specific approaches based on predominant mechanisms (volume overload, atrial fibrillation, etc.)
3. CKD with heart failure:
   • Non-steroidal MRAs may offer advantages due to lower hyperkalemia risk
   • SGLT2 inhibitors provide significant cardiorenal protection
   • Careful dosing of ARNI based on kidney function

6.3 Patient-Specific Considerations

Beyond heart failure phenotype, several patient factors should influence treatment selection:

1. Age:
   • Biomarker-guided therapy appears more beneficial in younger patients (<75 years)
   • Older patients may require more careful medication titration but still benefit from comprehensive GDMT
2. Comorbidities:
   • Diabetes: SGLT2 inhibitors provide particular benefit
   • Hypertension: ARNIs and MRAs offer additional blood pressure control
   • Atrial fibrillation: Rate control remains essential alongside GDMT
3. Tolerability:
   • Endocrine side effects: Eplerenone or finerenone preferred over spironolactone in younger men
   • Hypotension: Sequential rather than simultaneous initiation may improve tolerability
   • Hyperkalemia risk: Non-steroidal MRAs may allow RAAS modulation in higher-risk patients